What is HC Wainwright's Estimate for REGENXBIO Q1 Earnings?

REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Investment analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of REGENXBIO in a research note issued to investors on Monday, March 17th. HC Wainwright analyst Y. Chen now anticipates that the biotechnology company will post earnings per share of ($1.21) for the quarter, up from their previous forecast of ($1.35). HC Wainwright currently has a "Buy" rating and a $34.00 target price on the stock. The consensus estimate for REGENXBIO's current full-year earnings is ($4.84) per share. HC Wainwright also issued estimates for REGENXBIO's Q2 2025 earnings at ($1.20) EPS, Q3 2025 earnings at ($1.20) EPS, Q4 2025 earnings at ($1.19) EPS and FY2025 earnings at ($4.80) EPS.

Several other research analysts also recently commented on the stock. The Goldman Sachs Group downgraded shares of REGENXBIO from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $38.00 to $14.00 in a report on Tuesday, February 11th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $30.00 price objective on shares of REGENXBIO in a report on Tuesday, January 21st. Chardan Capital reaffirmed a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a report on Thursday. Morgan Stanley raised their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, March 14th. Finally, Raymond James initiated coverage on shares of REGENXBIO in a report on Friday, February 7th. They issued an "outperform" rating and a $27.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $33.88.

Remove Ads

REGENXBIO Trading Down 1.4 %

Shares of RGNX stock traded down $0.12 during trading hours on Wednesday, hitting $8.24. 2,493,911 shares of the company were exchanged, compared to its average volume of 711,047. The firm has a fifty day simple moving average of $7.30 and a 200 day simple moving average of $8.88. The stock has a market capitalization of $408.25 million, a price-to-earnings ratio of -1.64 and a beta of 1.35. REGENXBIO has a 52-week low of $5.62 and a 52-week high of $22.42.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $21.21 million during the quarter, compared to analyst estimates of $23.70 million.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. FMR LLC lifted its holdings in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 1,656 shares during the last quarter. GAMMA Investing LLC grew its position in REGENXBIO by 273.1% in the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock worth $27,000 after acquiring an additional 2,510 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in REGENXBIO in the fourth quarter worth $54,000. Dynamic Technology Lab Private Ltd purchased a new position in REGENXBIO in the fourth quarter worth $79,000. Finally, Laurion Capital Management LP purchased a new position in REGENXBIO in the fourth quarter worth $79,000. 88.08% of the stock is owned by institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.